Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE/ no PQC; HCP reports that the patient received their second dose of GARDASIL 9 at a shorter than recommended interval. No additional information was provided. No additional AE/ no PQC Date of first dose: 01/23/2026 Date of second dose: 02/04/2026; This Spontaneous report was received from other health professional and referred to a 44 -year-old patient of unknown gender. The patient's medical history, past medications and concomitant medications were not reported. On 23-Jan-2026, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9)(Dose Text: 0.5 ml/ series) (lot number, expiration date, administration route and anatomical location were not reported) as prophylaxis. Later, on 04-Feb-2026, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9)(Dose Text: 0.5 ml/ series) (lot number, expiration date, administration route and anatomical location were not reported) as prophylaxis. The reporter stated that the patient received their second dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9) at a shorter than recommended interval. No additional information was provided, and no additional adverse events were reported.